This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chen, P. L. Articles by Moore, D. H. Search for Related Content PubMed PubMed Citation Articles by Chen, P. L. Articles by Moore, D. H.

Identification of the Virions in the in Vitro L1210(V) Leukemia Cell Lines by Morphological, Virological, and Immunological Techniques¹

Institute for Medical Research, Camden, New Jersey 08130 [P. L. C., N. H. S., B. K., D. H. M.], and Sloan-Kettering Institute for Cancer Research, Walker Laboratory, Rye, New York 10580 [D. J. H.]

In vitro L1210(V) cell lines contained abundant intracytoplasmic A-particles, numerous C-type particles, a small number of B-type particles, and occasional intracisternal A-particles. The intracytoplasmic A-particles were incorporated into both spiked (B-type) and smooth-surfaced (C-type) particles formed at the budding site. Both B- and C-type particles also developed by gradual accumulation of nucleoid material. The particles, particularly the C-type, exhibited a wide range of densities. The cells showed strong surface immunofluorescence for both murine mammary tumor virus and Gross murine leukemia virus antigens and variable degrees of cytoplasmic immunofluorescence for the protein antigens (p1 to p6) of Rauscher leukemia virus. The cells, the culture supernatant, and the purified virus each gave positive reactions with murine mammary tumor virus and murine leukemia virus antisera by immunodiffusion. The viral particles failed to infect C57BL, C57BL/6 x DBA/2F₁ (hereafter called BD2F₁), BALB/c, Af, and RIIIf mice. However, the cells were highly tumorigenic in BD2F₁ mice, moderately tumorigenic in BALB/c mice, but not tumorigenic in C57BL, Af, and RIIIf mice.

¹ Supported in part by National Cancer Institute Grant CA-08740; by General Research Support Grant FR-5582, NIH; by Grant-in-Aid M-43 from the State of New Jersey; by National Cancer Institute Grant CA-08748; and by the American Cancer Society Grant 1C-66N.

² To whom requests for reprints should be addressed, at Institute for Medical Research, Camden, N. J. 08103.

Received 2/11/74. Accepted 11/26/74.